menu
    • menu

    Company profile for Axplora

    Axplora-PSE
    News
    Axplora initiates global investments exceeding €100m in 2025

    08 Oct 2025

    // PRESS RELEASE

    Axplora Announces €6.5 Million Investment at Vizag Site

    05 Aug 2025

    // PRESS RELEASE

    Axplora Doubles Farmabios Footprint with €35M Expansion

    04 Jul 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Axplora

    Contact Supplier

    Website

    BIO Partnering at JPM

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.pharmacompass.com/video-pharmareel/axplora-farmabios-pharmazell-and-novasep/pioneering-innovative-api-manufacturing-solutions

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Axplora is your partner of choice for complex APIs.

    Related CompaniesRelated Companies

    About

    Axplora, created from the merger of Farmabios, Novasep & PharmaZell, is a leading API manufacturing partner to the world’s leading pharma & biotech companies, delivering top-quality APIs on time & at scale, to the highest industry standards. It is dedicated to helping pharma companies make critical medicines safely to benefit patients. Leveraging our combined expertise & manufacturing capabilities across 9 industrial sites in the EU & India & an R&D facility in the USA, it offers CDMO services for small molecule APIs & biopharmaceuticals to innovators as well as APIs that address lifestyle-induced respiratory, inflammatory & liver diseases.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    AxploraGermany Flag
    Country
    Country
    Germany
    Address
    Address
    Headquarters, HochstraB-Süd 7, 83064 Raubling
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.axplora.com
    Linkedin
    Linkedin
    https://www.linkedin.com/company/axplora
    youtube
    YouTube
    http://www.youtube.com/@axplora5386
    Twitter
    Twitter
    Contact Info
    Others

    Instagram : https://www.instagram.com/axplora.group/

    Facebook : https://www.facebook.com/profile.php?id=100086944601878

    YouTube : https://www.youtube.com/channel/UCTuVYD8er8sbIdDE9QYksQA 

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    INTERVIEW #SpeakPharma

    read-more
    read-more
    "Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"

    mic"Axplora’s leading position in ADCs and how it is well-placed to serve the burgeoning GLP1 market"

    This week, SpeakPharma interviews Martin Meeson, CEO of Axplora, a leading and reliable API manufacturing partner to some of the world’s biggest pharma and biotech companies. Meeson discusses Axplora’s expansion in the antibody-drug-conjugate (ADC) space and how it is well-placed to serve the exciting market for glucagon-like peptide 1 (GLP-1) drugs with its industrial footprint and purification technologies across several sites. 🔑 HIGHLIGHTS// API manufacturing partner to some of the world’s biggest pharma and biotech companies As a leader in the pharmaceutical industry, what inspired you to join Axplora? And, what do you consider the most rewarding aspect of your role as its CEO? When you look at Axplora as the custodian of strong brands like Farmabios, Pharmazell and Novasep you cannot help but be intrigued by what such breadth of offering and depth of technical expertise can achieve. Well, I was certainly intrigued! As a leader in the pharma space, the opportunity to guide an organization with several decades of experience is inspiring for me. For example, our site in Leverkusen was founded over 150 years ago by Alfred Nobel. With every meeting and site visit, I get increasingly impressed by the capabilities of the people that I meet. Now, it is my job to make sure that these capabilities are given the best opportunity to serve. In this sector, we have the privilege of working with our partners to supply and develop medicines that have such a positive impact on people’s lives. This for me is the most rewarding thing that we do. Sometimes the work that we do can seem a little far away from the patient. I always take time to remind myself, my staff, and hopefully also your readers of what we are doing and how our work impacts others. 🔑 HIGHLIGHTS// strong brands like Farmabios, Pharmazell and Novasep / positive impact on people’s lives How have recent industry developments influenced both API manufacturing and CDMO sectors, and what specific strategies has Axplora implemented to adapt to these changing market dynamics while maintaining its commitment to quality and innovation? As a CDMO, when you partner with us, there is always a focus on reliable supply, and we are still haunted by the challenges all of us faced during the pandemic. At Axplora, we have implemented numerous initiatives to increase the robustness of supply, particularly in looking at advances in sourcing and horizontal integration both within and across our network. At the same time, we have a strong focus on the impact that we are having on the planet and Axplora’s work in this area is tremendous — from increasing the amount and efficacy of waste management, notably the current programs around solvent recovery and recycling, to implementing more environment-friendly technologies such as electrochemistry. I am particularly excited by the cutting-edge work on moving to completely new processes that are water-based rather than solvent-based, creating a step change in impact for us and our partners. In addition, as a CDMO you have to constantly look at where your services fit within evolving markets. Axplora’s expansion in the ADC sector is an excellent example of tracking and investing in emerging technologies. Of note also is the current demand for GLP-1 medicines, and Axplora is well-placed to serve this exciting market with our industrial footprint in small molecules and purification technologies across several sites in our network. 🔑 HIGHLIGHTS// increase the robustness of supply / efficient waste management programs and environment-friendly technologies Can you discuss any recent advancement or breakthrough in API manufacturing or CDMO services at Axplora that have contributed to the company’s success? Our investment in ADC expansion is a key strength. Our Novasep business has some of the world’s leading capabilities in API manufacturing and purification. It is known worldwide for these capabilities. With increasing demand for GLP-1 drugs and the amazing impact they are having on patients globally, we are ready to support this growth across our extensive network. The race to oral dose medicines in this space is particularly exciting, and Axplora is looking forward to treating the vast patient population in diabetes and obesity. 🔑 HIGHLIGHTS// expansion in the ADC sector / treat the vast patient population in diabetes and obesity Looking ahead, what are some of the trends or developments you foresee in API manufacturing and CDMO services, and how is Axplora preparing to stay ahead of the curve in this ever-evolving pharmaceutical landscape? Whilst the landscape is evolving rapidly, regulations are not necessarily able to keep pace with the development of new molecules. The pandemic revealed that things can move more quickly. When I look at the challenging new regulation in adjacent spaces like cell therapy, I wonder how that pace can be applied to our sectors. To that end, you have to remain agile and responsive to customer needs. We have to ensure we invest to grow our capacity in the right areas. Our recent investments in Farmabios in Gropello Cairoli (Italy) to support our thriving steroids business and in Pharmazell in Vizag (India) to advance our specialty business are clear indications of how we can do this very successfully. It would be easier if I could point to just one thing that we are doing, but that is not how we win. The only way to stay ahead is by making a myriad of large and small adjustments and evolutions and that is where the Axplora group excels. Finally, one element I should mention is that we are part of a global supply chain. Therefore, our broad network stands ready to supply medicines to multiple geographies. Our investments reflect our worldwide customer base and ambitions. We are here to serve our partners and their patients. 🔑 HIGHLIGHTS// recent investments in Farmabios in Italy and Pharmazell in India / ready to supply medicines to multiple geographies

    Impressions: 3402

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/axplora-s-leading-position-in-adcs-and-how-it-is-well-placed-to-serve-the-burgeoning-glp1-market

    #SpeakPharma With Axplora
    23 May 2024
    Share info Share

    VLOG #PharmaReel

    read-more

    ReelPharmaPioneering Innovative API Manufacturing SolutionsPioneering Innovative API Manufacturing Solutions

    Pioneering Innovative API Manufacturing Solutions
    Pioneering Innovative API Manufacturing Solutions

    reelPioneering Innovative API Manufacturing Solutions

    Pioneer of world-class API manufacturing solutions with ADC, steroids and flow chemistry expertise, empowering 900+ customers.

    Impressions: 1656

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-74273.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-18364.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Services for Pharmaceuticals 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-91740.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    CDMO Services for ADCs 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-12663.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Finorga GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-22830.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Farmabios GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-52441.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    PharmaZell GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-7993.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Novasep GMP Certificate 2022

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-1822.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Seripharm GMP Certificate 2021

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-25093.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Martin Meeson Appointed as CEO of Axplora

    read-more

      https://www.pharmacompass.com/pdf/party/content/axplora-party-content-75596.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    PharmaZell & Novasep Announce the Closing of their Merger.

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmazell-gmbh-party-content-1649482221.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    In Negotiations with Novasep for Complex Small Molecules & ADCs

    read-more

      https://www.pharmacompass.com/pdf/party/content/pharmazell-gmbh-party-content-1631849200.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    CDMO Activity Tracker: Veranova, ChemExpress invest in ADC facilities; Cohance to set up oligonucleotide facility in India

    The contract development and manufacturing organization (CDMO) sector has emerged as a key partner in new drug development. This was evident from the strategic investments, partnerships, and expansions witnessed in the third quarter (Q3) of 2025. Several CDMOs, such as Cohance Lifesciences, Fermion Oy, Axplora, AGC Pharma Chemicals invested in new projects. Others, including Veranova, Aenova, and Biosynth, expanded capacities, while Ofichem strengthened its footprint with the acquisition of Avivia BV. CDMOs like Fareva, Evonik, and Samsung Biologics forged strategic partnerships for growth. During Q3, the sector continued to adopt artificial intelligence (AI). This prompted the US Food and Drug Administration (FDA) to issue guidance that recognizes the increasing use of AI and data analytics in drug development.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Cohance, Veranova invest in bioconjugation suites in US; ChemExpress inks ADC deal Earlier this year, Indian drugmaker Suven Pharmaceuticals Limited merged with  leading CDMO Cohance Lifesciences Limited. The merged entity — Cohance Lifesciences — has invested US$ 10 million in a current Good Manufacturing Practice (cGMP) bioconjugation suite at its subsidiary NJ Bio in Princeton, New Jersey.  NJ Bio is executing a major program for an existing innovator client with multiple antibody-drug conjugate (ADC) candidates. Cohance also announced an INR 230 million (approximately US$ 2.58 million) investment in a cGMP oligonucleotide facility at its Hyderabad (India) site. Veranova’s Devens (Massachusetts) site successfully passed a routine FDA cGMP surveillance inspection with a “No Action Indicated” (NAI) classification. Earlier, the company had initiated a US$ 50 million investment to expand its ADC and bioconjugate capabilities at its Devens site. This includes a 9,000-square-foot facility expansion with a new process development lab, two additional cGMP suites, and state-of-the-art bioconjugation development and manufacturing capabilities. These initiatives strengthen the site’s highly potent API (HPAPI) and ADC development and manufacturing capabilities. Biosynth has expanded its Berlin facility with a new GMP bioconjugation suite. The expansion supports the company’s manufacturing capabilities in conjugate vaccines, conjugate drugs, activated polyethylene glycol (PEGs), and polymer-based drug delivery excipients. ChemExpress, Mabwell Bioscience, and Insilico Medicine have entered into a strategic partnership to jointly develop a large ADC compound library and advance next-generation ADC candidates. The collaboration combines Mabwell’s antibody and ADC technology, Insilico’s AI-powered drug design platform, and ChemExpress’s expertise in linker-payload chemistry. Together, they aim to build a complete, AI-driven ADC development model that accelerates discovery, optimization, and commercialization. This partnership is expected to enhance R&D efficiency and deliver safer, more effective cancer treatments.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available) Fermion, Axplora, Aenova increase API manufacturing capacities; ICE Pharma expands India facility Finnish CDMO Fermion Oy has launched a renovation project at its Hanko (Finland) production site to modernize its API manufacturing capabilities. This expansion is part of Fermion's broader strategy to increase production, enhance flexibility in the manufacturing of both existing and future pharmaceutical products, and enable potential contract manufacturing opportunities. German CDMO Axplora has announced a €6.5 million (approximately US$ 7.5 million) investment to expand its API manufacturing capacity at its Vizag site in India. This expansion aims to strengthen both production capabilities and supply chain resilience. India-based Aarti Pharmalabs has inaugurated the first phase of its greenfield manufacturing facility in Gujarat (India). This expansion aims to bolster Aarti's CDMO and contract manufacturing organization (CMO) services, targeting a revenue goal of INR 10 billion (approximately US$ 112 million). Snapdragon Chemistry, which was acquired by Cambrex in 2023, has expanded its Massachusetts facility to better support peptide drug development and manufacturing. With this upgrade, the company can now handle peptide projects from early development through full-scale manufacturing. Italy-headquartered ICE Pharma has expanded its Raichem facility in India. The new facility will enhance the production of ursodeoxycholic acid (UDCA), an API it derives from chicken bile. This expansion increases the site’s raw UDCA output by 120 metric tons annually. Spain-headquartered AGC Pharma Chemicals inaugurated a new advanced manufacturing plant in Barcelona, with an investment of €110 million (approximately US$ 128.3 million). The plant spans 7,500 square meters and integrates cutting-edge technologies to support the entire drug development lifecycle — from R&D to commercial manufacturing. This represents a 30 percent increase in the company’s production capacity and introduces a segment dedicated to HPAPIs. Germany-headquartered Aenova has launched a new hot melt extrusion platform at its Regensburg (Germany) site. This new equipment enables the production of advanced drug formulations, while handling all testing and quality checks in-house. The move strengthens Aenova’s capabilities in developing and manufacturing complex medications. US-based Cytovance Biologics has introduced in-house formulation development services, enhancing its role as a comprehensive partner for biologic drug developers. These services utilize quality-by-design principles to ensure speed, safety, and precision in current and future client programs.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Ofichem acquires Avivia BV; Evonik, Samsung Biologics form strategic collaborations Europe-based CDMO Ofichem Group announced the acquisition of Avivia BV, a formulation development company in the Netherlands. This acquisition is part of Ofichem’s strategy to become a fully integrated provider of development solutions across both drug substance and drug product, with a focus on complex formulations. Ofichem has also acquired Meribel Pharma Solutions’ site in Uppsala (Sweden) to strengthen its support for biotech innovators and expand its presence in the Nordic region.  Simtra BioPharma Solutions has acquired a 65-acre property near its Bloomington, Indiana (US) facility, adding over 300,000 square feet of potential expansion space. With this site, Simtra now has the flexibility to rapidly expand in the US. German specialty chemicals company Evonik is partnering with German biotech Ethris to develop and commercialize a next-generation lipid nanoparticle (LNP) platform for delivering nucleic acid therapies. Evonik will assist in formulation using Ethris’ SNaP LNP technology. The LNP market alone is projected to grow to US$2.3 billion by 2032. Luxembourg-headquartered Fareva has partnered with Zhaoke Ophthalmology to expand its footprint in China’s pharma market. Zhaoke will act as Fareva’s go-to partner for customers seeking pharmaceutical manufacturing in China. Samsung Biologics has signed a 1.8 trillion won (US$ 1.3 billion) manufacturing agreement with an undisclosed US-based drugmaker. And UK-based eXmoor Pharma has partnered with Anthony Nolan to provide end-to-end services for cell therapy developers.  View CDMO Activity Tracker for Q3 2025 (Free Excel Available)  Our view The global CDMO market, valued at around US$ 255 billion in 2025, is projected to grow to over US$ 465 billion by 2032. Significantly, about 60 percent of new drug approvals in the US and over 65 percent in Europe now involve CDMO support. The developments outlined above underscore the increasing role CDMOs are playing today in bringing about growth and innovation in the pharmaceutical industry.  
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3248

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-chemexpress-invest-in-adc-facilities-cohance-to-set-up-oligonucleotide-facility-in-india

    #PharmaFlow by PHARMACOMPASS
    16 Oct 2025
    Share Share
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 8812

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4792

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4818

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Axplora initiates global investments exceeding €100m in 2025
    Axplora initiates global investments exceeding €100m in 2025

    08 Oct 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-initiates-global-investments-exceeding-e100m-in-2025/

    PRESS RELEASE
    08 Oct 2025
    Share Share
    Axplora Announces €6.5 Million Investment at Vizag Site
    Axplora Announces €6.5 Million Investment at Vizag Site

    05 Aug 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-e6-5-million-investment-at-vizag-site-and-fda-inspection-success-across-indian-operations/

    PRESS RELEASE
    05 Aug 2025
    Share Share
    Axplora Doubles Farmabios Footprint with €35M Expansion
    Axplora Doubles Farmabios Footprint with €35M Expansion

    04 Jul 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-further-40m-expansion-at-farmabios-to-double-footprint-and-fuel-long-term-growth/

    PRESS RELEASE
    04 Jul 2025
    Share Share
    Axplora’s Chasse-sur-Rhône CDMO Site in France Passes Inspection
    Axplora’s Chasse-sur-Rhône CDMO Site in France Passes Inspection

    04 Jun 2025

    // PRESS RELEASE

    https://www.axplora.com/axploras-chasse-sur-rhone-site-successfully-passes-its-ninth-consecutive-regulatory-inspection/

    PRESS RELEASE
    04 Jun 2025
    Share Share
    Axplora Launches Payload Manufacturing Workshop in France
    Axplora Launches Payload Manufacturing Workshop in France

    04 Mar 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-expands-commercial-payload-production-capabilities-at-le-mans-to-strengthen-its-leading-position-in-adc-manufacturing/#:~:text=Axplora%2C%20a%20global%20leader%20in,Le%20Mans%20site%20(France).

    PRESS RELEASE
    04 Mar 2025
    Share Share
    Axplora Boosts GLP-1 Manufacturing with €50M Investment in France
    Axplora Boosts GLP-1 Manufacturing with €50M Investment in France

    13 Feb 2025

    // PRESS RELEASE

    https://www.axplora.com/axplora-announces-e50-million-investment-in-glp-1-manufacturing-at-mourenx-france-site/

    PRESS RELEASE
    13 Feb 2025
    Share Share

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Axplora full-view
    Antibody-Drug Conjugate (ADC) Development
    full-view
    Complex Active pharmaceutical ingredients
    full-view
    Custom Manufacturing of Complex & Original Molecules
    full-view
    Small Molecule API Development Services
    full-view
    Separation & Purification of APIs
    full-view
    Continuous Processes For Hazardous Reactions
    full-view
    Hazardous Chemistry services
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    FDA

    read-more
    read-more

    01

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2022-06-30

    Axplora

    City : Raubling

    State :

    Country/Area : Germany

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2022-06-30

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2021-10-01

    Axplora

    City : Gropello Cairoli

    State :

    Country/Area : Italy

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2021-10-01

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2020-02-20

    Axplora

    City : Chennai

    State :

    Country/Area : India

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2020-02-20

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2019-09-20

    Axplora

    City : Mourenx

    State :

    Country/Area : France

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2019-09-20

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-09-20

    Axplora

    City : Gropello Cairoli

    State :

    Country/Area : Italy

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2019-09-20

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2018-12-14

    Axplora

    City : Visakhapatnam

    State :

    Country/Area : India

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2018-12-14

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : No Action Indicated

    Inspection End Date : 2018-06-22

    Axplora

    City : Chasse Sur Rhone

    State :

    Country/Area : France

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : No Action Indicated

    Inspection End Date : 2018-06-22

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-03-15

    Axplora

    City : Le Mans

    State :

    Country/Area : France

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2018-03-15

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-09-22

    Axplora

    City : Raubling

    State :

    Country/Area : Germany

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-09-22

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    FDA Audited

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-08-11

    Axplora

    City : Chennai

    State :

    Country/Area : India

    Zip :

    District :

    Center :

    Project Area : Drug Quality Assurance

    District Decision : Voluntary Action Indicated

    Inspection End Date : 2017-08-11

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    EDQM

    read-more
    read-more

    01

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : 23MPP078HFR...

    EudraGMDP Key : 168398

    Country : France

    Issue Date : 2024-03-18

    Post Code :

    NCA Ref : 662019322000...

    City : Mourenx

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/26/H...

    EudraGMDP Key : 167910

    Country : Italy

    Issue Date : 2024-01-26

    Post Code :

    NCA Ref : 170851391407...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/275/...

    EudraGMDP Key : 167894

    Country : Italy

    Issue Date : 2023-11-28

    Post Code :

    NCA Ref : 170851391407...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : DE_BY_04_GM...

    EudraGMDP Key : 162949

    Country : Germany

    Issue Date : 2023-08-17

    Post Code :

    NCA Ref : 00004738

    City : Raubling

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : 20MPP051HFR...

    EudraGMDP Key : 161171

    Country : France

    Issue Date : 2023-06-05

    Post Code :

    NCA Ref : 662019322000...

    City : Chasse Sur Rhone

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    06

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/15/H...

    EudraGMDP Key : 157365

    Country : Italy

    Issue Date : 2023-01-20

    Post Code :

    NCA Ref : ATS Pavia Re...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    07

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/249/...

    EudraGMDP Key : 157368

    Country : Italy

    Issue Date : 2022-12-16

    Post Code :

    NCA Ref : ATS Pavia Re...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    08

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/243/...

    EudraGMDP Key : 159733

    Country : Italy

    Issue Date : 2022-12-05

    Post Code :

    NCA Ref : ATS Pavia Re...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    09

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : IT-API/167/...

    EudraGMDP Key : 159795

    Country : Italy

    Issue Date : 2022-08-12

    Post Code :

    NCA Ref : ATS Pavia Re...

    City : Gropello Cairoli

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    10

    GMP Certified

    EU
    arrow
    BIO Partnering at JPM
    Not Confirmed

    Axplora

    Type : GMP Certificates

    Number : 21MPP074HFR...

    EudraGMDP Key : 143124

    Country : France

    Issue Date : 2022-01-06

    Post Code :

    NCA Ref : 401 791 959 ...

    City : POMPEY

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    WHO-GMP

    read-more
    read-more

    01

    WHO GMP Certified

    Switzerland
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Axplora

    Name and address of WHO GMP certified Manufacturer : M/s. Pharmazell (India) Private Limited, Plot No. B5 & B6, Madras Export Processing Zone, Mepz, Tambaram, Chennai – 600 045.

    Country : Germany

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    GDUFA

    read-more
    read-more

    01

    GDUFA fees paid

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Paid in : 2024

    Axplora

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : Finorga

    Business Address : 497 Route de Givors Chasse-s...

    FEI Number : 3002806990

    Country : Germany

    Paid in : 2024

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    02

    GDUFA fees paid

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Paid in : 2024

    Axplora

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : Farmabios S.p.A.

    Business Address : via Pavia 1 Gropello Cairoli...

    FEI Number : 3002806965

    Country : Germany

    Paid in : 2024

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    03

    GDUFA fees paid

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Paid in : 2024

    Axplora

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : PharmaZell (India) Private Lim...

    Business Address : Plot No. B5 & B6, MEPZ, Tamb...

    FEI Number : 3003602532

    Country : Germany

    Paid in : 2024

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    04

    GDUFA fees paid

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Paid in : 2024

    Axplora

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : PharmaZell (India) Private Lim...

    Business Address : Plot No.115, Ramky Pharma Ci...

    FEI Number : 3008248967

    Country : Germany

    Paid in : 2024

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    05

    GDUFA fees paid

    USA
    arrow
    BIO Partnering at JPM
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothAxplora is your partner of choice for complex APIs.

    Paid in : 2024

    Axplora

    API Manufacturer : API MANUFACTURE

    FDF Manufacturer :

    Facility Name : PharmaZell GmbH

    Business Address : Rosenheimer Str.43 Raubling ...

    FEI Number : 3003725792

    Country : Germany

    Paid in : 2024

    Axplora CB

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ABOUT THIS PAGE

    Contact Axplora and get a quotation

    Axplora is a supplier offers 140 products (APIs, Excipients or Intermediates).

    Find a price of Acetylcysteine bulk with DMF, CEP, JDMF offered by Axplora

    Find a price of Betamethasone Valerate bulk with DMF, CEP, JDMF offered by Axplora

    Find a price of Medroxyprogesterone Acetate bulk with DMF, CEP, JDMF offered by Axplora

    Find a price of Mesalazine bulk with DMF, CEP, JDMF offered by Axplora

    Find a price of Triamcinolone Acetonide bulk with DMF, CEP, JDMF offered by Axplora

    Find a price of Beclomethasone Dipropionate bulk with DMF, CEP offered by Axplora

    Find a price of Betamethasone Dipropionate bulk with DMF, CEP offered by Axplora

    Find a price of Budesonide bulk with DMF, CEP offered by Axplora

    Find a price of Carbocisteine bulk with CEP, JDMF offered by Axplora

    Find a price of Clobetasol Propionate bulk with DMF, JDMF offered by Axplora

    Find a price of Difluprednate bulk with DMF, JDMF offered by Axplora

    Find a price of Fluocinolone Acetonide bulk with DMF, JDMF offered by Axplora

    Find a price of Fluocinonide bulk with DMF, JDMF offered by Axplora

    Find a price of Fluticasone Propionate bulk with DMF, CEP offered by Axplora

    Find a price of Formoterol Fumarate bulk with DMF, CEP offered by Axplora

    Find a price of Fulvestrant bulk with DMF, CEP offered by Axplora

    Find a price of Megestrol Acetate bulk with DMF, CEP offered by Axplora

    Find a price of Methylene Blue bulk with DMF, CEP offered by Axplora

    Find a price of Methylprednisolone Acetate bulk with DMF, CEP offered by Axplora

    Find a price of Mometasone Furoate bulk with DMF, CEP offered by Axplora

    Find a price of Paclitaxel bulk with DMF, CEP offered by Axplora

    Find a price of Prednisolone Acetate bulk with DMF, CEP offered by Axplora

    Find a price of Propafenone Hydrochloride bulk with DMF, CEP offered by Axplora

    Find a price of Teriflunomide bulk with DMF, CEP offered by Axplora

    Find a price of Triamcinolone Hexacetonide bulk with DMF, CEP offered by Axplora

    Find a price of Ursodeoxycholic Acid bulk with CEP, JDMF offered by Axplora

    Find a price of Amcinonide bulk with JDMF offered by Axplora

    Find a price of Atenolol bulk with JDMF offered by Axplora

    Find a price of Balsalazide Disodium bulk with DMF offered by Axplora

    Find a price of Beclomethasone Dipropionate bulk with DMF offered by Axplora

    Find a price of Busulfan bulk with DMF offered by Axplora

    Find a price of Cannabidiol bulk with DMF offered by Axplora

    Find a price of Carbocisteine bulk with JDMF offered by Axplora

    Find a price of Celecoxib bulk with DMF offered by Axplora

    Find a price of Chlormadinone Acetate bulk with JDMF offered by Axplora

    Find a price of Cholic Acid bulk with CEP offered by Axplora

    Find a price of Clocortolone Pivalate bulk with DMF offered by Axplora

    Find a price of Cortienic Acid bulk with DMF offered by Axplora

    Find a price of Cyproterone Acetate bulk with DMF offered by Axplora

    Find a price of Cystine bulk with CEP offered by Axplora

    Find a price of Desonide bulk with DMF offered by Axplora

    Find a price of Desoximetasone bulk with DMF offered by Axplora

    Find a price of Dexamethasone bulk with DMF offered by Axplora

    Find a price of Diflucortolone Valerate bulk with JDMF offered by Axplora

    Find a price of Diltiazem Hydrochloride bulk with CEP offered by Axplora

    Find a price of Esmolol Hydrochloride bulk with DMF offered by Axplora

    Find a price of Exemestane bulk with DMF offered by Axplora

    Find a price of Fludrocortisone Acetate bulk with DMF offered by Axplora

    Find a price of Flumethasone bulk with DMF offered by Axplora

    Find a price of Flunisolide bulk with DMF offered by Axplora

    Find a price of Fluorometholone bulk with DMF offered by Axplora

    Find a price of Flurandrenolone bulk with DMF offered by Axplora

    Find a price of Fluticasone Furoate bulk with DMF offered by Axplora

    Find a price of Halcinonide bulk with DMF offered by Axplora

    Find a price of Hydrocortisone bulk with DMF offered by Axplora

    Find a price of Hydrocortisone Acetate bulk with CEP offered by Axplora

    Find a price of Icosapent Ethyl bulk with DMF offered by Axplora

    Find a price of Indapamide bulk with CEP offered by Axplora

    Find a price of L-Cysteine Hydrochloride bulk with CEP offered by Axplora

    Find a price of Loteprednol Etabonate bulk with DMF offered by Axplora

    Find a price of Medroxyprogesterone Acetate bulk with DMF offered by Axplora

    Find a price of Megestrol Acetate bulk with CEP offered by Axplora

    Find a price of Melphalan Hydrochloride bulk with DMF offered by Axplora

    Find a price of Mesalazine bulk with JDMF offered by Axplora

    Find a price of Methyl Testosterone bulk with DMF offered by Axplora

    Find a price of Methylprednisolone Hemisuccinate bulk with CEP offered by Axplora

    Find a price of Mivacurium Chloride bulk with DMF offered by Axplora

    Find a price of Mometasone Furoate bulk with DMF offered by Axplora

    Find a price of Prednicarbate bulk with CEP offered by Axplora

    Find a price of Prednisolone Valerate Acetate bulk with JDMF offered by Axplora

    Find a price of Tirofiban Hydrochloride Monohydrate bulk with DMF offered by Axplora

    Find a price of Triamcinolone Acetonide bulk with CEP offered by Axplora

    Find a price of Triamcinolone Diacetate bulk with DMF offered by Axplora

    Find a price of Ursodeoxycholic Acid bulk with CEP offered by Axplora

    Find a price of Japanese Pharmacopoeia Diflorasone Acetate bulk with JDMF offered by Axplora

    Find a price of Hydrocortisone Acetate bulk offered by Axplora

    Find a price of 16Alpha-Hydroxyprednisolone bulk offered by Axplora

    Find a price of 6-Methyluracil bulk offered by Axplora

    Find a price of Acetylcysteine bulk offered by Axplora

    Find a price of Amifostine bulk offered by Axplora

    Find a price of Balsalazide Disodium bulk offered by Axplora

    Find a price of Beclomethasone Dipropionate bulk offered by Axplora

    Find a price of Betahistine Dihydrochloride bulk offered by Axplora

    Find a price of Betahistine Dimesilate bulk offered by Axplora

    Find a price of Betamethasone bulk offered by Axplora

    Find a price of Brexanolone bulk offered by Axplora

    Find a price of Brinzolamide bulk offered by Axplora

    Find a price of Budesonide bulk offered by Axplora

    Find a price of Carbocysteine Lysine bulk offered by Axplora

    Find a price of Cefmetazole Sodium bulk offered by Axplora

    Find a price of Cefminox Sodium bulk offered by Axplora

    Find a price of Celecoxib bulk offered by Axplora

    Find a price of Chenodeoxycholic Acid bulk offered by Axplora

    Find a price of Cholic Acid bulk offered by Axplora

    Find a price of Clobetasol Propionate bulk offered by Axplora

    Find a price of Clobetasone Butyrate bulk offered by Axplora

    Find a price of Delmadinone acetate bulk offered by Axplora

    Find a price of Dexamethasone Sodium Phosphate bulk offered by Axplora

    Find a price of Diflorasone bulk offered by Axplora

    Find a price of Difluprednate bulk offered by Axplora

    Find a price of Encorafenib bulk offered by Axplora

    Find a price of Eravacycline bulk offered by Axplora

    Find a price of Etoricoxib bulk offered by Axplora

    Find a price of Flumethasone Pivalate bulk offered by Axplora

    Find a price of Fluocortolone Caproate bulk offered by Axplora

    Find a price of Fluocortolone Pivalate bulk offered by Axplora

    Find a price of Fluprednidene Acetate bulk offered by Axplora

    Find a price of Guanfacine bulk offered by Axplora

    Find a price of Halometasone bulk offered by Axplora

    Find a price of Letrozole bulk offered by Axplora

    Find a price of Lysine bulk offered by Axplora

    Find a price of Lysine Acetate bulk offered by Axplora

    Find a price of Lysine Hydrochloride bulk offered by Axplora

    Find a price of Magnesium Orotate bulk offered by Axplora

    Find a price of Mesalazine bulk offered by Axplora

    Find a price of Methylprednisolone bulk offered by Axplora

    Find a price of Methylprednisolone Aceponate bulk offered by Axplora

    Find a price of Nitroglycerin bulk offered by Axplora

    Find a price of Olaparib bulk offered by Axplora

    Find a price of Omadacycline bulk offered by Axplora

    Find a price of Omega-3-Acid Ethyl Esters 90 bulk offered by Axplora

    Find a price of Osaterone acetate bulk offered by Axplora

    Find a price of Paramethasone Acetate bulk offered by Axplora

    Find a price of Prednisolone bulk offered by Axplora

    Find a price of Prednisolone Acetate bulk offered by Axplora

    Find a price of Prednisolone Sodium Metasulfobenzoate bulk offered by Axplora

    Find a price of Propafenone Hydrochloride bulk offered by Axplora

    Find a price of Prucalopride Succinate bulk offered by Axplora

    Find a price of Revefenacin bulk offered by Axplora

    Find a price of Ruxolitinib Phosphate bulk offered by Axplora

    Find a price of Salmeterol Xinafoate bulk offered by Axplora

    Find a price of Selinexor bulk offered by Axplora

    Find a price of Tauroursodeoxycholic Acid bulk offered by Axplora

    Find a price of Testosterone Cypionate bulk offered by Axplora

    Find a price of Tirofiban bulk offered by Axplora

    Find a price of Triamcinolone bulk offered by Axplora

    Find a price of Triamcinolone Acetonide bulk offered by Axplora

    Find a price of Vamorolone bulk offered by Axplora

    Find a price of Zavegepant HCl bulk offered by Axplora

    Find a price of Zinc Orotate bulk offered by Axplora

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search